A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. A cross sectional study’ – a correspondence

With great interest, we read the article by Su et al . [1] . This article is a single-center cross-sectional study involving an analysis of the prognosis of neoadjuvant chemotherapy versus upfront surgical treatment for resectable pancreatic ductal adenocarcinoma. The authors collected clinical data of patients with stage I and stage II pancreatic ductal adenocarcinoma who received treatment from a tertiary hospital from 2013 to 2020, and a total of 159 patients were eligible after exclusion, including 46 patients (29%) in the neoadjuvant chemotherapy (NAC) group and 113 patients (71%) in the upfront resection (UR) group. They found that NAC is superior to UR in resectable pancreatic cancer with better survival. This is a great fi nding; however, after carefully reading the article, we would like to raise the following questions regarding some details